Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Drop in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 433,200 shares, a drop of 29.3% from the May 31st total of 612,500 shares. Based on an average trading volume of 717,900 shares, the days-to-cover ratio is currently 0.6 days.

Vincerx Pharma Stock Up 9.5 %

Shares of VINC opened at $0.81 on Monday. Vincerx Pharma has a twelve month low of $0.57 and a twelve month high of $9.37. The company has a market capitalization of $23.92 million, a P/E ratio of -0.45 and a beta of 1.41. The firm has a 50 day moving average of $0.73 and a 200 day moving average of $2.06.

Vincerx Pharma (NASDAQ:VINC) last posted its earnings results on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). On average, sell-side analysts expect that Vincerx Pharma will post -0.62 EPS for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vincerx Pharma in a research note on Tuesday, April 9th.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Vanguard Group Inc. lifted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 666,995 shares of the company’s stock after acquiring an additional 153,575 shares during the quarter. Vanguard Group Inc. owned 3.12% of Vincerx Pharma worth $3,375,000 as of its most recent filing with the Securities & Exchange Commission. 44.02% of the stock is owned by hedge funds and other institutional investors.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.